Zurcher Kantonalbank Zurich Cantonalbank lowered its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 12.2% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 19,432 shares of the company’s stock after selling 2,696 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in IDEXX Laboratories were worth $6,416,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. boosted its holdings in shares of IDEXX Laboratories by 6.0% in the 1st quarter. BlackRock Inc. now owns 7,868,095 shares of the company’s stock valued at $1,905,968,000 after buying an additional 443,250 shares during the last quarter. State Street Corp boosted its holdings in shares of IDEXX Laboratories by 0.8% in the 1st quarter. State Street Corp now owns 3,801,209 shares of the company’s stock valued at $920,805,000 after buying an additional 29,361 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of IDEXX Laboratories by 1.7% in the 1st quarter. Geode Capital Management LLC now owns 1,577,807 shares of the company’s stock valued at $381,790,000 after buying an additional 26,141 shares during the last quarter. Blair William & Co. IL boosted its holdings in shares of IDEXX Laboratories by 1.1% in the 1st quarter. Blair William & Co. IL now owns 1,563,254 shares of the company’s stock valued at $378,683,000 after buying an additional 17,274 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its holdings in shares of IDEXX Laboratories by 740.5% in the 1st quarter. Alliancebernstein L.P. now owns 1,264,276 shares of the company’s stock valued at $306,258,000 after buying an additional 1,113,849 shares during the last quarter. 88.58% of the stock is owned by institutional investors.
In related news, VP Giovani Twigge sold 14,070 shares of the firm’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $307.73, for a total value of $4,329,761.10. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Jonathan W. Ayers sold 13,600 shares of the firm’s stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $286.07, for a total value of $3,890,552.00. Following the completion of the transaction, the director now owns 810,467 shares in the company, valued at approximately $231,850,294.69. The disclosure for this sale can be found here. Insiders have sold a total of 106,182 shares of company stock worth $31,409,008 in the last quarter. Company insiders own 2.53% of the company’s stock.
IDXX stock opened at $397.75 on Friday. The company has a debt-to-equity ratio of 7.06, a current ratio of 0.85 and a quick ratio of 0.60. The stock has a market capitalization of $31.77 billion, a price-to-earnings ratio of 74.82, a PEG ratio of 5.75 and a beta of 0.81. The business’s fifty day moving average price is $335.38 and its two-hundred day moving average price is $286.60. IDEXX Laboratories, Inc. has a fifty-two week low of $168.65 and a fifty-two week high of $407.86.
IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Friday, July 31st. The company reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.55. The firm had revenue of $637.20 million for the quarter, compared to analysts’ expectations of $589.98 million. IDEXX Laboratories had a return on equity of 264.71% and a net margin of 17.78%. The company’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same quarter last year, the business earned $1.43 EPS. Research analysts expect that IDEXX Laboratories, Inc. will post 4.98 EPS for the current year.
Several equities research analysts have issued reports on IDXX shares. BidaskClub downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 6th. Stifel Nicolaus raised their price target on IDEXX Laboratories from $280.00 to $375.00 and gave the company a “buy” rating in a report on Thursday. TheStreet raised IDEXX Laboratories from a “c+” rating to a “b-” rating in a report on Thursday, April 30th. Finally, Bank of America raised their price target on IDEXX Laboratories from $300.00 to $390.00 and gave the company a “buy” rating in a report on Monday, July 20th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. IDEXX Laboratories currently has a consensus rating of “Buy” and a consensus target price of $317.14.
About IDEXX Laboratories
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Read More: Understanding Price to Earnings Ratio (PE)
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.